vTv Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

vTv Therapeutics (Nasdaq: VTVT) said management will participate in two investor conferences in late February and early March 2026. Events: Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 26, 2026, 11:20 AM ET, virtual, presentation only) and TD Cowen 46th Annual Health Care Conference (Mar 3, 2026, 9:50 AM ET, Boston, presentation and 1x1 meetings). Webcasts will be available for both events per the company.

News Market Reaction – VTVT

-7.18%

2 alerts

-7.18% News Effect

-3.5% Trough Tracked

-$11M Valuation Impact

$138M Market Cap

0.2x Rel. Volume

On the day this news was published, VTVT declined 7.18%, reflecting a notable negative market reaction. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $11M from the company's valuation, bringing the market cap to $138M at that time.

Data tracked by StockTitan Argus on the day of publication.

HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences:

Oppenheimer 36th Annual Healthcare Life Sciences Conference
Date: Thursday, February 26, 2026
Time: 11:20 AM ET
Format: Presentation Only
Location: Virtual
Webcast Link

TD Cowen 46th Annual Health Care Conference
Date: Tuesday, March 3, 2026
Time: 9:50 AM ET
Format: Presentation and 1x1 Meetings
Location: Boston, MA
Webcast Link

About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

FAQ

When will vTv Therapeutics (VTVT) present at the Oppenheimer conference in 2026?

vTv will present on Thursday, February 26, 2026 at 11:20 AM ET. According to vTv, the appearance is virtual and the company will deliver a presentation-only session with a webcast available for investors.

What is the schedule for vTv Therapeutics (VTVT) at the TD Cowen Health Care Conference?

vTv management is scheduled for Tuesday, March 3, 2026 at 9:50 AM ET. According to vTv, the participation includes a presentation plus one-on-one meetings in Boston, with a webcast link provided.

Will the vTv (VTVT) presentations in February–March 2026 be available via webcast?

Yes, both events will offer webcasts for the presentations. According to vTv, the Oppenheimer session is virtual and the TD Cowen session will also provide a webcast link for remote investors.

What topics will vTv Therapeutics (VTVT) likely cover in the Feb–Mar 2026 investor presentations?

vTv will discuss corporate progress and clinical development plans, focusing on cadisegliatin for T1D. According to vTv, management presentations typically cover program updates, timelines, and investor Q&A opportunities.

How can investors access vTv Therapeutics (VTVT) presentation materials from the Feb 26 and Mar 3, 2026 events?

Investors can access live webcasts and likely archived presentation materials via the company webcast links. According to vTv, webcast links are provided for both the Oppenheimer and TD Cowen conference appearances.